|
MBLAC2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.45659999909398E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.63870000481037E-08 |
| Normal-vs-Stage2 |
2.178800E-03 |
| Normal-vs-Stage3 |
4.46159997835593E-09 |
| Normal-vs-Stage4 |
1.29770000301122E-08 |
| Stage1-vs-Stage2 |
6.033800E-02 |
| Stage1-vs-Stage3 |
5.136000E-01 |
| Stage1-vs-Stage4 |
1.588570E-01 |
| Stage2-vs-Stage3 |
3.796100E-02 |
| Stage2-vs-Stage4 |
1.017840E-02 |
| Stage3-vs-Stage4 |
4.069200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.96489996179872E-09 |
| Normal-vs-AfricanAmerican |
1.423200E-03 |
| Normal-vs-Asian |
1.62893999999802E-05 |
| Caucasian-vs-AfricanAmerican |
4.049000E-01 |
| Caucasian-vs-Asian |
3.245000E-01 |
| AfricanAmerican-vs-Asian |
9.300800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.74709998982337E-09 |
| Normal-vs-Female |
5.34699950982542E-10 |
| Male-vs-Female |
6.744100E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.28079999728703E-08 |
| Normal-vs-Age(41-60Yrs) |
1.75699998994361E-09 |
| Normal-vs-Age(61-80Yrs) |
1.20780000001375E-06 |
| Normal-vs-Age(81-100Yrs) |
2.441600E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.710000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.393600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.982200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.861200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.102200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.710200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.460000E-02 |
| Classical-VS-Follicular |
7.338100E-02 |
| Classical-VS-Other |
3.248600E-01 |
| Classical-VS-Normal |
3.20509999984786E-07 |
| Tall-VS-Follicular |
1.918540E-03 |
| Tall-VS-Other |
8.732600E-01 |
| Tall-VS-Normal |
8.44420000589707E-09 |
| Follicular-VS-Other |
1.487760E-01 |
| Follicular-VS-Normal |
1.028860E-04 |
| Other-VS-Normal |
5.175100E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.4070000053934E-08 |
| Normal-vs-N1 |
2.82659995409773E-09 |
| N0-vs-N1 |
2.029600E-02 |
|
|
